Table 1

Baseline disease characteristics of the patients

Completer

(n = 16)

Dropout

(n = 10)


age (years)

36.3 ± 7.5

38.4 ± 11.0

Male gender (n, %)

14 (87.5%)

6 (60%)

disease duration (years)

13 ± 7.7

15 ± 10.8

BASDAI (0 to 10)

6.3 ± 0.9

7.0 ± 1.4

BASFI (0 to 10)

5.3 ± 1.9

6.8 ± 1.6

BASMI (0 to 10)

3.9 ± 2.2

3.7 ± 1.3

CRP (mg/l)

20.8 ± 17.7

19.3 ± 16.7

ASDAS units

3.9 ± 0.7

4.3 ± 0.9

HLA positive (n patients, %)

13 (81.3%)

10 (100%)


Baseline disease characteristics of the patients who completed Year 7 of the study (n = 16) and of those who discontinued during the seven years of treatment with etanercept. None of these parameters was significantly different when the two investigated groups were compared (all P >0.05)

Baraliakos et al. Arthritis Research & Therapy 2013 15:R67   doi:10.1186/ar4244

Open Data